Amalfi Trial: Mail ECG Patch Boosts AF Diagnosis
- A mail-based atrial fibrillation (AF) screening program utilizing 14-day ECG-patch monitoring resulted in a modest but notable long-term increase in AF diagnosis and subsequent anticoagulation treatment among older...
- atrial fibrillation,a common heart rhythm disorder,dramatically increases stroke risk,but ofen presents without noticeable symptoms or occurs sporadically,making detection challenging.
- The AMALFI (Asymptomatic atrial Fibrillation Monitoring in Primary Care) trial was an investigator-initiated, parallel-arm, unblinded randomized controlled trial conducted across 27 primary care practices in the United Kingdom.
“`html
Long-Term ECG Patch Screening Boosts Atrial Fibrillation Detection in Older Adults
A mail-based atrial fibrillation (AF) screening program utilizing 14-day ECG-patch monitoring resulted in a modest but notable long-term increase in AF diagnosis and subsequent anticoagulation treatment among older patients identified as being at moderate to high risk of stroke. The findings, presented at ESC Congress 2024 and published concurrently in JAMA, suggest a viable strategy for proactive stroke prevention. JAMA
atrial fibrillation,a common heart rhythm disorder,dramatically increases stroke risk,but ofen presents without noticeable symptoms or occurs sporadically,making detection challenging. Customary screening methods may miss these intermittent episodes. The AMALFI trial investigated whether extended, remote ECG monitoring could improve AF detection rates in a high-risk population.
The AMALFI Trial: Design and Methodology
The AMALFI (Asymptomatic atrial Fibrillation Monitoring in Primary Care) trial was an investigator-initiated, parallel-arm, unblinded randomized controlled trial conducted across 27 primary care practices in the United Kingdom. Researchers identified eligible participants – older adults at moderate to high stroke risk – and randomly assigned them to either a screening group or a usual care control group. The screening group received a 14-day continuous ECG monitoring patch delivered by mail.
Professor Louise Bowman, Chief Investigator from Oxford Population Health, explained the study’s core question: “AF is associated wiht an increased risk of stroke, but AF can be arduous to detect as it frequently enough occurs without symptoms and/or infrequently. screening for AF has been proposed as a way to prevent strokes but many short or infrequent asymptomatic AF episodes may be missed. The advent of new monitoring technology has enabled longer-duration screening. The AMALFI trial was designed to assess the long-term efficacy of remote screening for asymptomatic AF in older individuals at increased risk of stroke using a 14-day continuous ECG monitoring patch.
“
Key Findings: Increased Diagnosis and Anticoagulation
The study demonstrated a statistically significant increase in AF diagnosis in the screening group compared to the control group. Specifically, the screening group experienced a higher rate of new AF diagnoses over a longer follow-up period. Importantly, this increased detection translated into a greater proportion of patients receiving appropriate anticoagulation therapy – a crucial step in reducing stroke risk.
While the increase was described as “modest,” researchers emphasize its clinical importance. Even a small percentage increase in AF detection and treatment can have a ample impact on public health, given the large number of individuals at risk of stroke. The study did not report specific numbers, but the JAMA publication will contain detailed data.
| Outcome | Screening Group | Control Group |
|---|---|---|
| New AF Diagnosis (Follow-up) | Data to be reported in JAMA | Data to be reported in JAMA |
| Anticoagulation Initiation | Data to be reported in JAMA | Data to be reported in JAMA |
Implications for Stroke Prevention
The AMALFI trial supports the growing evidence base for proactive AF screening, particularly in populations at elevated stroke risk. The use of